1. Home
  2. DH vs ANNX Comparison

DH vs ANNX Comparison

Compare DH & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Definitive Healthcare Corp.

DH

Definitive Healthcare Corp.

HOLD

Current Price

$1.22

Market Cap

283.1M

Sector

Technology

ML Signal

HOLD

Logo Annexon Inc.

ANNX

Annexon Inc.

HOLD

Current Price

$5.59

Market Cap

730.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DH
ANNX
Founded
2011
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
283.1M
730.4M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
DH
ANNX
Price
$1.22
$5.59
Analyst Decision
Hold
Strong Buy
Analyst Count
5
6
Target Price
$3.43
$16.50
AVG Volume (30 Days)
364.0K
2.1M
Earning Date
05-25-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
63.28
42.94
EPS
N/A
N/A
Revenue
$241,521,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$1.21
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.07
$1.29
52 Week High
$4.70
$7.18

Technical Indicators

Market Signals
Indicator
DH
ANNX
Relative Strength Index (RSI) 22.47 53.10
Support Level N/A $4.69
Resistance Level $2.96 $7.18
Average True Range (ATR) 0.12 0.31
MACD -0.02 0.05
Stochastic Oscillator 21.64 84.74

Price Performance

Historical Comparison
DH
ANNX

About DH Definitive Healthcare Corp.

Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Share on Social Networks: